Inequities in Antiviral Therapy for Diabetic Individuals Affected by COVID-19
Andreea Fitero, Nicoleta Negruţ, Carmen Delia Nistor-Cseppento, Delia MirelaTit, Paul Andrei Negru, Cristian Bustea, Andrei Flavius Radu, Simona Bungău
Abstract
Diabetes patients are more vulnerable to COVID-19 infections, which can cause serious respiratory conditions. In this study, the effect of the antiviral medication with molnupiravir and favipiravir was compared in COVID-19 patients with underlying diabetes. The current investigation included a cohort of 100 people who had been diagnosed with diabetes, had a SARS-CoV-2 infection, and had been admitted sequentially. The antiviral drugs were administered to these patients according to regional reco
Topics & Concepts
Coronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineAntiviral therapyVirologyViral therapyIntensive care medicineInternal medicineVirusDiseaseInfectious disease (medical specialty)OutbreakChronic hepatitisCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchDiabetes and associated disorders